Interestingly, the SURPASS-2 trial found that patients on tirzepatide 5 mg experienced less nausea (17.4%) and vomiting (5.7%) compared to those on semaglutide 1 mg, who reported 19.2% nausea and 8.1% vomiting, despite tirzepatide leading to greater weight loss
One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and - and -cell function and reduces endogenous glucose release in patients with type 2 diabetes
Johansson KA, Dursun U, Jordan N, Gu G, Beermann F, Gradwohl G, et al
The straps should remain attached to the plate
T., & Casteleyn, L
Yes, stopping semaglutide carries no dangerous withdrawal or organ damage, but appetite and cravings typically return within days to weeks